Synonyms: VX-121 | VX121
vanzacaftor is an approved drug
Compound class:
Synthetic organic
Comment: Vanzacaftor (VX-121) is a cystic fibrosis transmembrane regulator (CFTR) protein modulator/corrector for class II CFTR mutations (the most common being F508del). The principal action of vanzacaftor is to restore the folding/trafficking of mutated CFTR to the plasma membrane. VX-121 also stimulates a K+ secretory current that is mediated by the large-conductance calcium-activated potassium channel (BKCa, KCa1.1) [2].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes. FDA (2024) |
International Nonproprietary Names ![]() |
|
INN number | INN |
11971 | vanzacaftor |
Synonyms ![]() |
VX-121 | VX121 |
Database Links ![]() |
|
CAS Registry No. | 2374124-49-7 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL5314934 |
DrugBank Ligand | DB18373 |
GtoPdb PubChem SID | 507750328 |
PubChem CID | 139399801 |
Search Google for chemical match using the InChIKey | VCSUIBJKYCVWNF-NRFANRHFSA-N |
Search Google for chemicals with the same backbone | VCSUIBJKYCVWNF |
Search PubMed clinical trials | vanzacaftor |
Search PubMed titles | vanzacaftor |
Search PubMed titles/abstracts | vanzacaftor |
UniChem Compound Search for chemical match using the InChIKey | VCSUIBJKYCVWNF-NRFANRHFSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | VCSUIBJKYCVWNF-NRFANRHFSA-N |